Showing results (281-290 of 323) with videos related to

Sort By:
Pageof 33
International Journal of Cancer|June 20, 2022
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based studyMonica Niger, Federico Nichetti, Andrea Casadei-Gardini, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2021
Synaptophysin expression in <sup>V600EBRAF-</sup>mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosisMatteo Fassan, Massimo Milione, Giulia Maddalena, et al.
Diagnostics (Basel, Switzerland)|November 27, 2024
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for <i>MGMT</i> Gene Promoter Hypermethylation DetectionMarco Macagno, Valeria Pessei, Noemi Congiusta, et al.
Therapeutic Advances in Medical Oncology|November 6, 2024
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burdenLeonardo Provenzano, Yong Xiang Gwee, Veronica Conca, et al.
JCO Precision Oncology|October 5, 2020
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 TrialElisa Fontana, Gift Nyamundanda, David Cunningham, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancersGiovanni Fucà, Romain Cohen, Sara Lonardi, et al.
British Journal of Cancer|September 3, 2019
CK7 and consensus molecular subtypes as major prognosticators in <sup>V600E</sup>BRAF mutated metastatic colorectal cancerFotios Loupakis, Paola Biason, Alessandra Anna Prete, et al.
The New England Journal of Medicine|May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal CancerKohei Shitara, Elena Elimova, Tianshu Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2019
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal CancerFilippo Pietrantonio, Riccardo Lobefaro, Maria Antista, et al.
Targeted Oncology|March 28, 2018
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss StudyMaria Di Bartolomeo, Monica Niger, Giuseppe Tirino, et al.
Pageof 33